Knight Therapeutics Inc. has announced a definitive agreement to acquire the Paladin business from Endo Operations Limited and Paladin Pharma Inc. in a deal valued at $120 million upfront, with potential additional contingent payments of up to US$15 million tied to future sales performance.
The Montreal-based specialty pharmaceutical company will pay the initial sum in cash, including $20 million for inventory. The acquisition targets Paladin's pharmaceutical portfolio, which generated revenues of $70 million in 2024, excluding discontinued products.
Jonathan Ross Goodman, Executive Chairman of Knight Therapeutics and co-founder of Paladin, expressed personal satisfaction with the deal: "The reunion of Paladin and Knight, two companies dear to me, is both financially attractive and personally gratifying."
Samira Sakhia, President and Chief Executive Officer of Knight, emphasized the strategic value of the acquisition: "This synergistic transaction adds critical mass and significantly increases the size of our Canadian business. In addition, the acquisition adds a portfolio of stable cash flow generating pharmaceuticals that will help fund our growth in Canada and Latin America."
Strategic Implications for Knight's Market Position
The acquisition represents a significant expansion of Knight's Canadian operations. Knight Therapeutics, which focuses on acquiring, in-licensing, and commercializing pharmaceutical products across Canada and Latin America, will strengthen its market presence through this transaction.
The deal brings together two companies with shared history through Goodman's leadership, potentially creating operational synergies based on familiar business models and corporate cultures. Knight's existing Latin American subsidiaries—United Medical, Biotoscana Farma, and Laboratorio LKM—complement this expanded Canadian footprint.
Financial Details and Timeline
The transaction structure includes the $120 million upfront payment plus the potential for up to US$15 million in additional payments contingent on meeting specific sales targets. The $70 million in annual revenue from Paladin's continuing product lines represents a significant addition to Knight's business.
RBC Capital Markets is serving as Knight's exclusive financial advisor for the transaction, with Davies Ward Phillips & Vineberg providing legal counsel. The companies expect the deal to close in mid-2025, subject to customary regulatory approvals including anti-trust clearance in Canada.
Market Context and Outlook
This acquisition occurs amid ongoing consolidation in the specialty pharmaceutical sector, as companies seek to build scale and diversify product portfolios. For Knight, the addition of Paladin's established products provides immediate revenue enhancement and cash flow stability to support the company's broader growth initiatives.
Knight Therapeutics trades on the Toronto Stock Exchange under the symbol GUD. The company has scheduled a conference call and audio webcast on March 11, 2025, at 8:30 am ET to discuss the acquisition details with investors and other interested parties.
The transaction reinforces Knight's position as a pan-American specialty pharmaceutical company with a strengthened presence in its home Canadian market while supporting its continued expansion throughout Latin America.
